版本:
中国

BRIEF-Astrazeneca announced new results data evaluating cost-effectiveness of synagis

March 28 Astrazeneca Plc:

* Astrazeneca - announced new results data evaluating cost-effectiveness of synagis for respiratory syncytial virus in preterm infants 29-34 weeks gestational age

* Astrazeneca - results showed synagis may reduce overall costs in infants born at 29-32 weeks gestational age who are less than 3 months of age over 1-year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐